US48301N1046
© BusinessWire
20.01.2026
KAPA
LISTED
XASE
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate in the DealFlow Discovery Conference, taking place Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ. Kairos Pharma Chief Scientific Officer Neil Bhowmick will deliver a...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
KAPA
LISTED
XASE
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer.
Kairos earned this recognition for its...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
KAPA
LISTED
XASE
Kairos Pharma Provides Shareholder Update
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below.
To our valued Kairos Pharma Shareholders,
This year, Kairos has been focused on exe...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
20.10.2025
KAPA
LISTED
XASE
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Societ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
07.10.2025
KAPA
LISTED
XASE
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos’s presentation, titled, “Preliminary safety and clinical activity from a P...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
KAPA
LISTED
XASE
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Kairos Pharma is hosting a virtual KOL (key...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
KAPA
LISTED
XASE
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate,...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
KAPA
LISTED
XASE
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference whi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
KAPA
LISTED
XASE
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte N...
Themefolio
Profiler
Peergroup
© Newsfile
28.07.2025
KAPA
LISTED
XASE
CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline
News Preview
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Ca...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
KAPA
LISTED
XASE
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
News Preview
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Kairos Pharma will pa...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
KAPA
LISTED
XASE
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
News Preview
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial d...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
03.06.2025
KAPA
LISTED
XASE
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill.
I...
Themefolio
Profiler
Peergroup
© Newsfile
06.05.2025
KAPA
LISTED
XASE
Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference
News Preview
Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:0...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
KAPA
LISTED
XASE
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill.
The poster is titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effect...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
KAPA
LISTED
XASE
Kairos Pharma Ltd. Provides Letter to Stockholders
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.:
To our valued stockholders,
As we reflect on the Company’s progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
KAPA
LISTED
XASE
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
KAPA
LISTED
XASE
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company’”), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, “Phase II study of Apalutamide with Carotuximab (ENV105) in Metastat...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
KAPA
LISTED
XASE
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events.
Highlights include:
March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, “Novel GITR Agonist KROS 101: A Dual...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
KAPA
LISTED
XASE
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a potentially significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC) patients. Recent findings published in Drug Resistance Updates highlight the...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
KAPA
LISTED
XASE
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from February 23-26, 2025. The data highligh...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
KAPA
LISTED
XASE
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat c...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
KAPA
LISTED
XASE
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
News Preview
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) ag...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
KAPA
LISTED
XASE
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii.
The talk, titled, “KROS 101: A Next-Generat...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
KAPA
LISTED
XASE
Kairos Pharma Provides Business Update and Outlook into 2025
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders:
Dear Kairos Pharma Shareholders,
The management team and Board of Directors o...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
KAPA
LISTED
XASE
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, Chief Scientific Officer, will present a corporate overview at the Lytham Partners Investor Healthcare Summit. The conference is being held virtually on January 13, 2025.
Event...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
KAPA
LISTED
XASE
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.
Cit...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2024
KAPA
LISTED
XASE
Kairos Pharma to Present at the LD Micro Main Event XVII
News Preview
LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard H...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
KAPA
LISTED
XASE
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
News Preview
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing D...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
KAPA
LISTED
XASE
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
News Preview
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
KAPA
LISTED
XASE
Kairos Pharma Prices $6.2 Million Initial Public Offering
News Preview
Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA” Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA”...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
